POXEL
Add to a list
To use this feature you must be a member
Log inSign up
7PO
FR0012432516
| Real-time BOERSE MUENCHEN Other stock markets | 5-day change | 1st Jan Change | ||
| 0.5920 EUR | -0.84% |  | +11.38% | +4.74% |
| Jul. 15 | Poxel: financing discussions being finalized | CF |
| Apr. 11 | Poxel: CDC falls below the 10% threshold | CF |
Valuation: Poxel
| Capitalization | 27.16M 29.32M | P/E ratio 2021 | -5.92x | P/E ratio 2022 | -0.87x |
|---|---|---|---|---|---|
| Enterprise value | 59.9M 64.65M | EV / Sales 2021 | 10.7x | EV / Sales 2022 | 88.9x |
| Free-Float | 99.57% | Yield 2021 * | - | Yield 2022 | - |
More valuation ratios * Estimated data
Chart: Poxel
Dynamic Chart
Latest news: Poxel
| Poxel: financing discussions being finalized | CF | |
| Poxel: CDC falls below the 10% threshold | CF | |
| Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI | |
| Poxel: share price rises, boosted by savings plan | CF | |
| Global markets live: Coty, Sanofi, Ford, Spotify, Tesla... |  | |
| Transcript : Poxel S.A., H1 2023 Earnings Call, Sep 26, 2023 | ||
| Poxel: losses widen, share price falls | CF | |
| Poxel S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI | |
| Poxel: financing secured until mid-2025 | CF | |
| Poxel: Bpifrance Investissem*nt down to less than 5%. | CF | |
| Poxel: published cash position for Q1 2023 | CF | |
| Global markets live: Burberry, Cisco, Walmart, Alibaba, Charles Schwab... | | |
| Poxel S.A. Auditor Raises 'Going Concern' Doubt | CI |
More news
Last Transcript: Poxel
Poxel S.A., H1 2023 Earnings Call, Sep 26, 2023
More transcripts
Analysts' recommendations: Poxel
| POXEL : Degroof Petercam reduces its target | CF |
More recommendations
Press Releases: Poxel
| Poxel Provides an Update on Its Financial Position for the Second Quarter and First Half of 2024 and Announces the Rescheduling of Its Annual General Meeting | BU | |
| Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update | BU | |
| Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release | BU | |
| Poxel to Report Its 2023 Annual Results by the End of April 2024 | BU | |
| Poxel Announces its Financial Calendar for 2024 | AQ |
More press releases
News in other languages: Poxel
More news
Quotes and Performance
| 1 week | +11.38% | ||
| 1 month | +24.25% | ||
| 3 months | -6.72% | ||
| 6 months | +31.21% | ||
| Current year | +4.74% |
More quotes
Course Extremes
1 week
0.49
0.69
1 month
0.46
0.69
More quotes
Managers and Directors: Poxel
| Director | Title | Age | Since |
|---|---|---|---|
Sebastien Bolze FOU | Founder | - | 09-03-05 |
Pascale Fouqueray-Grellier FOU | Founder | 61 | 09-03-05 |
Sophie Hallakou-Bozec FOU | Founder | - | 09-03-05 |
| Manager | Title | Age | Since |
|---|---|---|---|
Thomas Kuhn FOU | Founder | 50 | 09-03-05 |
Mohammed Khoso Baluch CHM | Chairman | 66 | 11-12-31 |
Richard Kender BRD | Director/Board Member | 68 | 15-03-11 |
More insiders
Bio Therapeutic Drugs
Add to a list Add to a list 0 selected To use this feature you must be a member Log inSign up | Change | 5d. change | 1-year change | 3-years change | Capi. ($) | |
|---|---|---|---|---|---|---|
VERTEX PHARMACEUTICALS INCORPORATED | +1.76% | +2.59% | +45.23% | +154.65% | 128B | |
REGENERON PHARMACEUTICALS, INC. | +1.21% | +3.24% | +48.65% | +90.36% | 116B | |
ARGENX SE | +1.61% | +11.59% | +4.75% | +83.41% | 30.49B | |
GENMAB A/S | +0.61% | +3.28% | -29.42% | -30.96% | 17.99B | |
BEIGENE, LTD. | -1.60% | +0.15% | -20.83% | -50.06% | 17.63B | |
WUXI APPTEC CO., LTD. | -0.56% | +9.44% | -40.98% | -71.80% | 16.46B | |
NEUROCRINE BIOSCIENCES, INC. | +8.14% | +4.52% | +47.62% | +59.21% | 14.25B | |
SAREPTA THERAPEUTICS, INC. | +0.92% | -2.86% | +33.30% | +108.98% | 13.45B | |
INSMED INCORPORATED | +3.64% | +1.46% | +241.57% | +213.26% | 11.73B | |
| Average | +1.72% | +1.66% | +36.66% | +61.90% | 40.71B | |
| Weighted average by Cap. | +1.53% | +1.86% | +38.17% | +95.63% |
See all sector performances
Financials
| 2021 | 2022 | |
|---|---|---|
| Net sales | 13.4M 14.46M | 674K 727K |
| Net income | -23.76M -25.65M | -31.4M -33.89M |
| Net Debt | 3M 3.24M | 32.74M 35.33M |
More financial data * Estimated data
Company Profile
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases.TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes.For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).
Employees
Sector
Calendar
2024-08-28 - Q2 2024 Sales and Revenue Release
More about the company
Quotes
| Date | Price | Change |
|---|---|---|
| 24-08-01 | 0.5920 € | -0.84% |
| 24-07-31 | 0.5970 € | +1.02% |
| 24-07-30 | 0.5910 € | -4.68% |
| 24-07-29 | 0.6200 € | +10.71% |
| 24-07-26 | 0.5600 € | +13.36% |
Real-time BOERSE MUENCHEN, August 01, 2024 at 12:13 pm EDT
More quotes
Income Statement and Estimates
More financial data
Quarterly earnings, Rate of surprise
Company calendar
- Stock Market
- Equities
- POXEL Stock
- 7PO Stock
